Concepedia
Statistics
Publications
9
Citations
719
H-Index
Active since
2011
Affiliations
Arqule (United States)(Current)
South Texas Accelerated Research Therapeutics
Fondazione IRCCS Istituto Nazionale dei Tumori
Emory University
Humanitas University
Julia Kazakin is an author at Arqule (United States) specializing in medicine, oncology, and pharmacology.
Publications per year
2011–2020
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer · 2018 · 380 citations · Full text
Medicine, Oncology, Pharmacology +17
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher et al. · British Journal of Cancer · 2017 · 95 citations · Full text
Medicine, Oncology, Pharmacology +14
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
Shubham Pant, Mansoor N. Saleh, Johanna C. Bendell et al. · Annals of Oncology · 2014 · 82 citations · Full text
Medicine, Oncology, Pharmacology +9
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma
Chiara Leoni, Giuseppe Gullo, Nicoletta Resta et al. · American Journal of Medical Genetics Part A · 2019 · 49 citations
Medicine, Gynecology, Oncology +17
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
Leslie G. Biesecker, Matthew Edwards, Sheridan O’Donnell et al. · Molecular Case Studies · 2020 · 42 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +10
1–5 of 9